insights_auto
Why is DEVA down 3.32%?
Dive Deeperchevron_right
DEVA:IST
Deva Holding AS
TRY 83.00
arrow_downward
-3.32%(-2.85) 1D
Oct 12, 6:10:00 PM GMT+3 · TRY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DEVA...
Open
TRY 85.85
High
TRY 86.25
Low
TRY 82.80
Mkt. cap
16.60B
Avg. vol.
660.43K
Volume
305.83K
52-wk high
TRY 109.30
52-wk low
TRY 57.50
EPS
-TRY 4.21
Shares outstanding
200.02M
No. of employees
3K
Open
TRY 85.85
High
TRY 86.25
Low
TRY 82.80
Mkt. cap
16.60B
Avg. vol.
660.43K
Volume
305.83K
52-wk high
TRY 109.30
52-wk low
TRY 57.50
EPS
-TRY 4.21
Shares outstanding
200.02M
No. of employees
3K
News stories
From web sources and news partners
bloomingbit
·
13 minutes ago
U.S. Stocks Turn Mixed; Nasdaq Falls 0.20%
Kitco
·
10 minutes ago
Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
Morningstar
·
51 minutes ago
Dow Jones Top Energy Headlines at 11 AM ET: Oil Prices Rebound Amid Persistent Middle East Supply Risks | Russia ...
TradeWinds News
·
3 days ago
Nordic American Tankers top stock as shipping crushes S&P 500 in unprecedented quarter
Profile
DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements.
A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas.
As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
About Deva Holding AS